Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Analytic inquiry: Molecular testing in lung cancer.

Zakowski MF.

Cancer Cytopathol. 2017 Jun;125(S6):470-476. doi: 10.1002/cncy.21866. Review.

2.

"…That which we call a rose…": A critical analysis of rapid on-site evaluation.

Zakowski MF.

Cancer Cytopathol. 2016 Dec;124(12):857-861. doi: 10.1002/cncy.21784. Epub 2016 Nov 11. No abstract available.

3.

Morphologic Accuracy in Differentiating Primary Lung Adenocarcinoma From Squamous Cell Carcinoma in Cytology Specimens.

Zakowski MF, Rekhtman N, Auger M, Booth CN, Crothers B, Ghofrani M, Khalbuss W, Laucirica R, Moriarty AT, Tabatabai ZL, Barkan GA.

Arch Pathol Lab Med. 2016 Oct;140(10):1116-20. doi: 10.5858/arpa.2015-0316-OA. Epub 2016 Aug 23.

4.

Cytology nomenclature and 2015 World Health Organization classification of lung cancer.

Zakowski MF.

Cancer Cytopathol. 2016 Feb;124(2):81-8. doi: 10.1002/cncy.21628. Epub 2015 Oct 13. Review. No abstract available.

5.

Imaging appearances of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia.

Foran PJ, Hayes SA, Blair DJ, Zakowski MF, Ginsberg MS.

Clin Imaging. 2015 Mar-Apr;39(2):243-6. doi: 10.1016/j.clinimag.2014.10.017. Epub 2014 Oct 30.

PMID:
25496668
6.

Low interobserver agreement in cytology grading of mucinous pancreatic neoplasms.

Sigel CS, Edelweiss M, Tong LC, Magda J, Oen H, Sigel KM, Zakowski MF.

Cancer Cytopathol. 2015 Jan;123(1):40-50. doi: 10.1002/cncy.21492. Epub 2014 Oct 29.

7.

Small-cell lung cancers in patients who never smoked cigarettes.

Varghese AM, Zakowski MF, Yu HA, Won HH, Riely GJ, Krug LM, Kris MG, Rekhtman N, Ladanyi M, Wang L, Berger MF, Pietanza MC.

J Thorac Oncol. 2014 Jun;9(6):892-6. doi: 10.1097/JTO.0000000000000142.

8.

Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature.

Kapur S, Xiao H, Zakowski MF, Hameed MR, Levin MB.

World J Oncol. 2014 Apr;5(2):81-89. doi: 10.14740/wjon779w. Epub 2014 May 6.

9.

Comparison of multiplanar reformatted CT lung tumor measurements to axial tumor measurement alone: impact on maximal tumor dimension and T stage.

Ridge CA, Huang J, Cardoza S, Zabor EC, Moskowitz CS, Zakowski MF, Ginsberg MS.

AJR Am J Roentgenol. 2013 Nov;201(5):959-63. doi: 10.2214/AJR.12.10033. Erratum in: AJR Am J Roentgenol. 2014 Jan;202(1):248.

PMID:
24147464
10.

The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey.

Paintal A, Raparia K, Zakowski MF, Nayar R.

Cancer Cytopathol. 2013 Dec;121(12):703-7. doi: 10.1002/cncy.21342. Epub 2013 Sep 4.

11.

Lung cancer in the era of targeted therapy: a cytologist's perspective.

Zakowski MF.

Arch Pathol Lab Med. 2013 Dec;137(12):1816-21. doi: 10.5858/arpa.2013-0029-RA. Epub 2013 Apr 18. Review.

PMID:
23597048
12.

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens P, Ross J, Miller V, Ginsberg M, Zakowski MF, Kris MG, Ladanyi M, Rizvi N.

Cancer Discov. 2013 Jun;3(6):630-5. doi: 10.1158/2159-8290.CD-13-0035. Epub 2013 Mar 26.

13.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riely GJ.

Clin Cancer Res. 2013 Apr 15;19(8):2240-7. doi: 10.1158/1078-0432.CCR-12-2246. Epub 2013 Mar 7.

14.

EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.

Arcila ME, Nafa K, Chaft JE, Rekhtman N, Lau C, Reva BA, Zakowski MF, Kris MG, Ladanyi M.

Mol Cancer Ther. 2013 Feb;12(2):220-9. doi: 10.1158/1535-7163.MCT-12-0620. Epub 2013 Jan 31.

15.

Lung carcinoma in the era of personalized medicine: the role of cytology.

Zakowski MF, Bibbo M.

Acta Cytol. 2012;56(6):587-9. doi: 10.1159/000345183. Epub 2012 Nov 24. No abstract available.

PMID:
23207435
16.

Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma.

Rekhtman N, Tafe LJ, Chaft JE, Wang L, Arcila ME, Colanta A, Moreira AL, Zakowski MF, Travis WD, Sima CS, Kris MG, Ladanyi M.

Mod Pathol. 2013 Apr;26(4):511-22. doi: 10.1038/modpathol.2012.195. Epub 2012 Nov 30. Erratum in: Mod Pathol. 2014 Jan;27(1):163.

17.

Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.

D'Angelo SP, Janjigian YY, Ahye N, Riely GJ, Chaft JE, Sima CS, Shen R, Zheng J, Dycoco J, Kris MG, Zakowski MF, Ladanyi M, Rusch V, Azzoli CG.

J Thorac Oncol. 2012 Dec;7(12):1815-1822. doi: 10.1097/JTO.0b013e31826bb7b2.

18.

Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.

Suehara Y, Arcila M, Wang L, Hasanovic A, Ang D, Ito T, Kimura Y, Drilon A, Guha U, Rusch V, Kris MG, Zakowski MF, Rizvi N, Khanin R, Ladanyi M.

Clin Cancer Res. 2012 Dec 15;18(24):6599-608. doi: 10.1158/1078-0432.CCR-12-0838. Epub 2012 Oct 10.

19.

Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.

Dogan S, Shen R, Ang DC, Johnson ML, D'Angelo SP, Paik PK, Brzostowski EB, Riely GJ, Kris MG, Zakowski MF, Ladanyi M.

Clin Cancer Res. 2012 Nov 15;18(22):6169-77. doi: 10.1158/1078-0432.CCR-11-3265. Epub 2012 Sep 26.

20.

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.

Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M, Paik PK, Zakowski MF, Kris MG, Ladanyi M.

Clin Cancer Res. 2012 Sep 15;18(18):4910-8. doi: 10.1158/1078-0432.CCR-12-0912. Epub 2012 Jul 3.

21.

Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma.

Hasanovic A, Ang D, Moreira AL, Zakowski MF.

Lung Cancer. 2012 Aug;77(2):299-305. doi: 10.1016/j.lungcan.2012.04.004. Epub 2012 Apr 26.

PMID:
22542171
22.

Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.

Rekhtman N, Paik PK, Arcila ME, Tafe LJ, Oxnard GR, Moreira AL, Travis WD, Zakowski MF, Kris MG, Ladanyi M.

Clin Cancer Res. 2012 Feb 15;18(4):1167-76. doi: 10.1158/1078-0432.CCR-11-2109. Epub 2012 Jan 6.

23.

Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.

Chaft JE, Arcila ME, Paik PK, Lau C, Riely GJ, Pietanza MC, Zakowski MF, Rusch V, Sima CS, Ladanyi M, Kris MG.

Mol Cancer Ther. 2012 Feb;11(2):485-91. doi: 10.1158/1535-7163.MCT-11-0692. Epub 2011 Dec 1.

24.

Correlation between tumor measurement on Computed Tomography and resected specimen size in lung adenocarcinomas.

Lampen-Sachar K, Zhao B, Zheng J, Moskowitz CS, Schwartz LH, Zakowski MF, Rizvi NA, Kris MG, Ginsberg MS.

Lung Cancer. 2012 Mar;75(3):332-5. doi: 10.1016/j.lungcan.2011.08.001. Epub 2011 Sep 3.

25.

Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens.

Sigel CS, Moreira AL, Travis WD, Zakowski MF, Thornton RH, Riely GJ, Rekhtman N.

J Thorac Oncol. 2011 Nov;6(11):1849-56. doi: 10.1097/JTO.0b013e318227142d.

26.

Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma.

Girard N, Sima CS, Jackman DM, Sequist LV, Chen H, Yang JC, Ji H, Waltman B, Rosell R, Taron M, Zakowski MF, Ladanyi M, Riely G, Pao W.

Eur Respir J. 2012 Feb;39(2):366-72. doi: 10.1183/09031936.00010111. Epub 2011 Jul 20.

27.

Role of cytology in the management of non-small-cell lung cancer.

Fischer AH, Cibas ES, Howell LP, Kurian EM, Laucirica R, Moriarty AT, Renshaw AA, Zakowski MF, Young NA.

J Clin Oncol. 2011 Aug 20;29(24):3331-2; author reply 3332-3. doi: 10.1200/JCO.2011.35.2534. Epub 2011 Jul 18. No abstract available.

PMID:
21768461
28.

The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.

Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, Creaney J, Lake RA, Zakowski MF, Reva B, Sander C, Delsite R, Powell S, Zhou Q, Shen R, Olshen A, Rusch V, Ladanyi M.

Nat Genet. 2011 Jun 5;43(7):668-72. doi: 10.1038/ng.855.

29.

Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.

D'Angelo SP, Pietanza MC, Johnson ML, Riely GJ, Miller VA, Sima CS, Zakowski MF, Rusch VW, Ladanyi M, Kris MG.

J Clin Oncol. 2011 May 20;29(15):2066-70. doi: 10.1200/JCO.2010.32.6181. Epub 2011 Apr 11.

30.

Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.

Rekhtman N, Brandt SM, Sigel CS, Friedlander MA, Riely GJ, Travis WD, Zakowski MF, Moreira AL.

J Thorac Oncol. 2011 Mar;6(3):451-8. doi: 10.1097/JTO.0b013e31820517a3.

31.

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.

Arcila ME, Oxnard GR, Nafa K, Riely GJ, Solomon SB, Zakowski MF, Kris MG, Pao W, Miller VA, Ladanyi M.

Clin Cancer Res. 2011 Mar 1;17(5):1169-80. doi: 10.1158/1078-0432.CCR-10-2277. Epub 2011 Jan 19.

32.

Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.

Janjigian YY, Park BJ, Zakowski MF, Ladanyi M, Pao W, D'Angelo SP, Kris MG, Shen R, Zheng J, Azzoli CG.

J Thorac Oncol. 2011 Mar;6(3):569-75. doi: 10.1097/JTO.0b013e318202bffe.

33.

Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans.

Reinersman JM, Johnson ML, Riely GJ, Chitale DA, Nicastri AD, Soff GA, Schwartz AG, Sima CS, Ayalew G, Lau C, Zakowski MF, Rusch VW, Ladanyi M, Kris MG.

J Thorac Oncol. 2011 Jan;6(1):28-31. doi: 10.1097/JTO.0b013e3181fb4fe2.

34.

Aspiration cytomorphology of fetal adenocarcinoma of the lung.

Geisinger KR, Travis WD, Perkins LA, Zakowski MF.

Am J Clin Pathol. 2010 Dec;134(6):894-902. doi: 10.1309/AJCP4T5SWATQLKTQ.

PMID:
21088152
35.

Primary lung adenocarcinomas in children and adolescents treated for pediatric malignancies.

Kayton ML, He M, Zakowski MF, Moreira AL, Lau C, Chou AJ, Merchant M, Merola PR, Wexler LH, La Quaglia MP, Travis WD, Ladanyi M.

J Thorac Oncol. 2010 Nov;5(11):1764-71. doi: 10.1097/JTO.0b013e3181f69f08.

36.

Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center.

D'Angelo SP, Park B, Azzoli CG, Kris MG, Rusch V, Ladanyi M, Zakowski MF.

J Thorac Cardiovasc Surg. 2011 Feb;141(2):476-80. doi: 10.1016/j.jtcvs.2010.08.026. Epub 2010 Oct 8.

37.

The role of fine needle aspiration cytology in the diagnosis and management of thymic neoplasia.

Zakowski MF, Huang J, Bramlage MP.

J Thorac Oncol. 2010 Oct;5(10 Suppl 4):S281-5. doi: 10.1097/JTO.0b013e3181f23e19.

38.

Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung.

Alam N, Gustafson KS, Ladanyi M, Zakowski MF, Kapoor A, Truskinovsky AM, Dudek AZ.

Clin Lung Cancer. 2010 Sep 1;11(5):E1-4. doi: 10.3816/CLC.2010.n.046.

PMID:
20837450
39.

Insulin-like growth factor-1 receptor expression in thymic malignancies.

Girard N, Teruya-Feldstein J, Payabyab EC, Riely GJ, Rusch VW, Kris MG, Zakowski MF.

J Thorac Oncol. 2010 Sep;5(9):1439-46. doi: 10.1097/JTO.0b013e3181e392a8.

40.
41.

Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis.

Solomon SB, Zakowski MF, Pao W, Thornton RH, Ladanyi M, Kris MG, Rusch VW, Rizvi NA.

AJR Am J Roentgenol. 2010 Jan;194(1):266-9. doi: 10.2214/AJR.09.2858.

42.

Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.

Girard N, Shen R, Guo T, Zakowski MF, Heguy A, Riely GJ, Huang J, Lau C, Lash AE, Ladanyi M, Viale A, Antonescu CR, Travis WD, Rusch VW, Kris MG, Pao W.

Clin Cancer Res. 2009 Nov 15;15(22):6790-9. doi: 10.1158/1078-0432.CCR-09-0644. Epub 2009 Oct 27.

43.

High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507).

Gong Y, Yao E, Shen R, Goel A, Arcila M, Teruya-Feldstein J, Zakowski MF, Frankel S, Peifer M, Thomas RK, Ladanyi M, Pao W.

PLoS One. 2009 Oct 6;4(10):e7273. doi: 10.1371/journal.pone.0007273.

44.

Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.

Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, Koutcher JA, Spassova M, Ouerfelli O, Mellinghoff IK, Zakowski MF, Politi KA, Pao W.

J Clin Invest. 2009 Oct;119(10):3000-10. doi: 10.1172/JCI38746. Epub 2009 Sep 14.

45.

An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors.

Chitale D, Gong Y, Taylor BS, Broderick S, Brennan C, Somwar R, Golas B, Wang L, Motoi N, Szoke J, Reinersman JM, Major J, Sander C, Seshan VE, Zakowski MF, Rusch V, Pao W, Gerald W, Ladanyi M.

Oncogene. 2009 Aug 6;28(31):2773-83. doi: 10.1038/onc.2009.135. Epub 2009 Jun 15.

46.

Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.

Zakowski MF, Hussain S, Pao W, Ladanyi M, Ginsberg MS, Heelan R, Miller VA, Rusch VW, Kris MG.

Arch Pathol Lab Med. 2009 Mar;133(3):470-7. doi: 10.1043/1543-2165-133.3.470.

47.

Evidence-based pathology and the pathologic evaluation of thymomas: transcapsular invasion is not a significant prognostic feature.

Gupta R, Marchevsky AM, McKenna RJ, Wick M, Moran C, Zakowski MF, Suster S.

Arch Pathol Lab Med. 2008 Jun;132(6):926-30. doi: 10.1043/1543-2165(2008)132[926:EPATPE]2.0.CO;2.

PMID:
18517274
48.

Evidence-based pathology and the pathologic evaluation of thymomas: the World Health Organization classification can be simplified into only 3 categories other than thymic carcinoma.

Marchevsky AM, Gupta R, McKenna RJ, Wick M, Moran C, Zakowski MF, Suster S.

Cancer. 2008 Jun 15;112(12):2780-8. doi: 10.1002/cncr.23492. Review.

49.

EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression.

Li AR, Chitale D, Riely GJ, Pao W, Miller VA, Zakowski MF, Rusch V, Kris MG, Ladanyi M.

J Mol Diagn. 2008 May;10(3):242-8. doi: 10.2353/jmoldx.2008.070178. Epub 2008 Apr 10.

50.

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.

Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, Herbst RS, Heller G, Ladanyi M, Pao W, Johnson DH.

J Clin Oncol. 2008 Mar 20;26(9):1472-8. doi: 10.1200/JCO.2007.13.0062.

PMID:
18349398

Supplemental Content

Loading ...
Support Center